For decades, “untreatable” was one of the words attached to Alzheimer’s disease. It described not only the limits of medicine, but the feeling that a diagnosis left families with little to do except prepare for decline.

That word is becoming harder to defend.

“Alzheimer’s is no longer an untreatable disease,” neurologist Jeffrey Cummings said in response to a 2026 analysis of the field. “It is now a disease with treatments that successfully interfere in the disease process.”[4]

That does not mean Alzheimer’s has been cured. It has not. The treatments available today are not right for everyone, work best in the early stages of disease, and carry meaningful risks and burdens. But they do mark a change in what medicine can do.

The FDA gave traditional approval to lecanemab, marketed as Leqembi, after a large Phase 3 study verified that it slowed clinical decline compared with placebo in people with mild cognitive impairment or mild Alzheimer’s dementia and confirmed amyloid pathology.[2] The FDA later approved donanemab, marketed as Kisunla, for people in the same early stages. In its trial, donanemab produced a statistically significant reduction in clinical decline.[3]

These medicines do not restore lost memory or stop Alzheimer’s forever. Their benefit is measured in slowing the disease’s progress, which can mean more time with greater independence and more time for families to make decisions together. They also require careful medical evaluation because side effects can include amyloid-related imaging abnormalities, or ARIA, a complication that can cause swelling or bleeding in the brain.[2][3]

That combination of benefit and limitation is exactly why this moment matters. The question is no longer whether Alzheimer’s biology can be influenced at all. The question is how much more can be done, how early treatment should begin, which people are most likely to benefit, and how to make the care safer and more accessible.

The research pipeline is answering those questions from many directions. A 2026 analysis from the Alzheimer’s Association counted 158 potential medicines in 192 clinical trials, a larger and more varied pipeline than a decade ago.[4] Alzheimer’s Research UK reported that 35% of the medicines in development were repurposed drugs, originally approved for another condition, while researchers are also testing therapies aimed at tau, inflammation, immune response, cognition, and combinations of treatments.[5]

That is where Leon Wong’s project offers an especially memorable glimpse of the next chapter. Wong, a senior at The King’s School in Connecticut, investigated whether two FDA-approved drugs used for idiopathic pulmonary fibrosis, pirfenidone and nintedanib, could reduce signs of damage in brain blood-vessel cells connected to vascular Alzheimer’s disease.[6]

Working with lab-grown cells and public genetic data, Wong studied the APOE4 risk variant and a pathway involving transforming growth factor beta, or TGF-beta. In his presentation, he reports that both drugs reduced markers associated with blood-brain-barrier and vascular degeneration in the cellular model.[6]

This is not evidence that either drug treats Alzheimer’s in people. It is not a reason to take a medication for an unapproved use. The project still needs independent replication, animal studies, and carefully designed human trials before anyone could know whether the idea benefits patients.

But it is a hopeful kind of research because it starts from a new assumption: the next useful Alzheimer’s treatment may not have to be invented from nothing. It may come from understanding the disease more precisely, noticing a connection between two biological problems, and testing whether an existing tool can be put to work in a new place.

The 2026 World Alzheimer Report describes this as a turning point. Its authors point to earlier diagnosis, disease-modifying treatments, risk reduction, and a growing number of clinical trials. They also make the necessary promise that keeps hope honest: progress must reach people through evidence, safety, inclusion, and access.[1]

So the most accurate sentence may be this: Alzheimer’s is no longer universally untreatable, but it is still profoundly under-treated. The work ahead is to turn early successes into better treatments for more people, at more stages of disease, while continuing to search for prevention and cures.

That is not false hope. It is a reason to keep going.

Source note

This is an original synthesis based on the 2026 World Alzheimer Report, FDA approval documents for lecanemab and donanemab, the Alzheimer’s Association’s 2026 pipeline summary, Alzheimer’s Research UK’s analysis of the 2026 pipeline, and Leon Wong’s Society for Science video presentation. The Nice News story was the discovery lead but is not linked or used as the reporting source.

The story deliberately distinguishes treatment from cure. Lecanemab and donanemab slow clinical decline in selected people with early Alzheimer’s disease; they do not reverse the disease. Wong’s findings are preclinical cell-culture results and should not be presented as an available treatment.

Sources